Insilico + CMS $1.2B CNS AI Drug Deal Explained (July 2026)
Insilico Medicine and China Medical System expanded their AI drug discovery collaboration July 12, 2026 with ~1.2B RMB milestones. What it is and why it matters.
Read the full articleYou might also wanna read
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generativ
Insilico’s Chinese partner returns for $177M pact to explore ‘mass market’ CNS indication
Pharma platform company China Medical System Holdings has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collabor
Takeda signs $600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japan
StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants,
China Medical System to pay Insilico up to $177 million for nervous system work
SHANGHAI, July 13 (Reuters) - Drugmaker China Medical System will pay Insilico Medicine up to about 1.2 billion yuan ($177 million) in miles
China Medical System to pay Insilico up to $177 million for nervous system work
SHANGHAI, July 13 (Reuters) - Drugmaker China Medical System will pay Insilico Medicine up to about 1.2 billion yuan ($177 million) in miles
Comments
Sign in to join the conversation.
No comments yet. Be the first.